Department of Nephrology-Dialysis-Transplantation, University Hospital of Liege (ULg CHU), Liege, Belgium.
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Clin Chim Acta. 2020 Mar;502:84-90. doi: 10.1016/j.cca.2019.12.008. Epub 2019 Dec 19.
Sclerostin is sometimes presented as a promising biomarker in assessing bone health both in the general population and chronic kidney disease patients. However, it is still unclear whether it has any true added value compared to existing bone biomarkers in predicting bone turnover and/or bone density in chronic kidney disease patients. A wealth of papers has been published to evaluate the association between sclerostin and vascular calcifications development or even as prognostic biomarker for mortality, but often with conflicting results. Standardization and harmonization of analytical techniques is a prerequisite to advance clinical knowledge in sclerostin.
骨硬化蛋白有时被认为是一种很有前途的生物标志物，可用于评估普通人群和慢性肾脏病患者的骨骼健康。然而，与现有的骨生物标志物相比，它在预测慢性肾脏病患者的骨转换和/或骨密度方面是否具有真正的附加价值仍不清楚。已经发表了大量的论文来评估骨硬化蛋白与血管钙化发展之间的关系，甚至将其作为死亡率的预后生物标志物，但结果往往存在矛盾。分析技术的标准化和协调是推进骨硬化蛋白临床知识的前提。
